Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 3 1Phase 2 1Phase 1 1

Status

Withdrawn 1Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

NET 4Gastrointestinal 4Endocrine 4Sarcoma 1Lymphoid 1CNS 1

Conditions

Neuroendocrine Tumors 10Gastro-enteropancreatic neuroendocrine tumor 4Pheochromocytoma 2Paraganglioma 2Vipoma 1Thymus Neoplasms 1Rhabdomyosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms, Unknown Primary 1Neoplasms 1Meningioma 1Lymphoma 1Insulinoma 1Gastrinoma 1Central Nervous System Neoplasms 1Carcinoma, Merkel Cell 1Carcinoid Tumor 1

Interventions

lutetium Lu 177 dotatate 8lanreotide 4copper dotatate CU-64 4Octreotide 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4pasireotide 3Magnetic Resonance Spectroscopy 3Lutetium-177 3Lutetium 3gallium Ga 68 dotatate 2amino-acid, glucose, and electrolyte solution 2Temozolomide 2Nivolumab 2Irinotecan 2Ga(III)-DOTATOC 2Everolimus 2Etoposide 2Carboplatin 2zimberelimab 1regorafenib 1pembrolizumab 1irinotecan sucrosofate 1folfirinox 1famitinib 1cabozantinib 1arginyllysine 1abemaciclib 1X-Rays 1Sunitinib 1Somatostatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Gastro-enteropancreatic neuroendocrine tumor × 177Lu-octreotide, DOTA(0)-Tyr(3)- × Clear all
NCT06441331 2026-05-01

KinLET

ITM Solucin GmbH

Phase 1 Recruiting
20 enrolled
CNSEndocrineGastrointestinalLymphoidNETSarcoma

Gastro-enteropancreatic neuroendocrine tumor, Lymphoma, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Neuroendocrine Tumors

NCT04919226 2025-09-10

COMPOSE

ITM Solucin GmbH

Phase 3 Active not recruiting
259 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT05359146 2024-04-19

Beta plus

University Hospital, Basel, Switzerland

Phase EARLY_PHASE1 Unknown
16 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT04915144 2023-02-21

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

British Columbia Cancer Agency

Phase 2 Withdrawn
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Vipoma, Insulinoma, Gastrinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡